LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Zai Lab Ltd ADR

Closed

SectorHealthcare

32.51 -5.14

Overview

Share price change

24h

Current

Min

32.38

Max

34.29

Key metrics

By Trading Economics

Income

7.7M

-41M

Sales

3.5M

110M

Profit margin

-37.032

Employees

1,869

EBITDA

1.4M

-55M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+48.77% upside

Dividends

By Dow Jones

Next Earnings

11 lis 2025

Market Stats

By TradingEconomics

Market Cap

-414M

3.8B

Previous open

37.65

Previous close

32.51

News Sentiment

By Acuity

50%

50%

172 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sie 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 sie 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 sie 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 sie 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 sie 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sie 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 sie 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 sie 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 sie 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 sie 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 sie 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 sie 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 sie 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 sie 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 sie 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 sie 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 sie 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 sie 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 sie 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 sie 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 sie 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 sie 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 sie 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 sie 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

48.77% upside

12 Months Forecast

Average 51 USD  48.77%

High 69 USD

Low 35 USD

Based on 8 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

172 / 372 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.